Month: August 2018

Stock Analysts

Alnylam Gets European Nod for First-Ever RNAi Therapeutic

August 31, 2018 0

Alnylam Pharmaceuticals, Inc. ALNY announced that the European Commission (EC) has granted marketing authorization for Onpattro (patisiran), the first ever RNA interference (RNAi) therapeutic, for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy. The European Medicines Agency reviewed patisiran under the accelerated assessment procedure […]

Stock Analysts

Bayer’s (BAYRY) Jivi Gets FDA Approval to Treat Hemophilia A

August 31, 2018 0

Bayer AG BAYRY announced that the FDA has approved Jivi (BAY94-9027) for the routine prophylactic treatment of hemophilia A in previously-treated adults and adolescents 12 years of age or older, in the United States. The FDA also approved Jivi for on-demand treatment and perioperative management of bleeding in the same population. Jivi is a long acting PEGylated recombinant human Factor VIII (rFVIII) replacement therapy. […]

Mergers & Acquisitions

BayMark Health Services Acquires Counseling Solutions Opioid Addiction Treatment Facilities in Georgia and North Carolina

August 31, 2018 0

BayMark Health Services Acquires Counseling Solutions Opioid Addiction Treatment Facilities in Georgia and North Carolina BayMark Health Services announced the acquisition of Counseling Solutions, a medication-assisted treatment provider with locations in Chatsworth, GA and Brasstown, NC. PR Newswire DALLAS, Aug. 31, 2018 DALLAS , Aug. […]

Stock Analysts

Bristol-Myers’ Sprycel Seeks Label Expansion in the U.S.

August 31, 2018 0

Bristol-Myers Squibb Company BMY announced that the FDA accepted its supplemental Biologics License Application (sBLA) for oncology drug, Sprycel. The sBLA seeks to get Sprycel’s label expansion for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy. The application was based on positive data from an ongoing phase II trial, CA180-372 (NCT01460160), evaluating the addition of Sprycel to a chemotherapy regimen modeled on a Berlin-Frankfurt-Munster high-risk backbone in pediatric patients with newly diagnosed Ph+ ALL […]

Technicals

Here’s Why DSW (DSW) is a Great Momentum Stock

August 31, 2018 0

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. […]

Technicals

Here’s Why Five9 (FIVN) is a Great Momentum Stock

August 31, 2018 0

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. […]